Predictors of In-hospital Mortality in Cardiogenic Shock Patients on Vasoactive or Inotropic Support

Area of Science:

• Cardiology
• Pharmacology
• Critical Care Medicine

Background:

• Inotropes are indicated for cardiogenic shock (CS) despite controversy.
• This study examines in-hospital mortality for CS patients receiving vasoactive inotropic medications.
• Focus is on SCAI stage B and C cardiogenic shock managed in a cardiac care unit.

Purpose of the Study:

• To evaluate in-hospital mortality associated with commonly used inotropes in cardiogenic shock.
• To assess the effect on mortality risk of dobutamine, dopamine, milrinone, and norepinephrine.
• To determine the safety and feasibility of inotropic therapy for SCAI stage B and C CS.

Main Methods:

• Retrospective evaluation of 342 patients with SCAI stage B and C cardiogenic shock.
• Analysis of patients receiving dobutamine, milrinone, dopamine, norepinephrine, or combinations.
• Utilized Cox proportional hazards models for mortality risk prediction.

Main Results:

• Overall in-patient mortality was 18%.
• Each 1 µg/kg/minute increase in dobutamine independently increased mortality risk by 15%.
• High-dose dobutamine (>3 µg/kg/minute) showed a 3-fold increased mortality risk; milrinone, norepinephrine, and dopamine were not independently associated with mortality.

Conclusions:

• In-hospital mortality for medically managed SCAI stage B and C CS patients on inotropes was consistent with prior studies.
• Dobutamine use was independently associated with increased mortality.
• Other vasoactive inotropic agents (milrinone, norepinephrine, dopamine) were not linked to mortality, supporting their continued use.